Released Jan 29, 2024, after the close
10-K filed Jan 29, 2024, 90 days after period end · 0001654954-24-000996
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.60M$3.60M derived−22.4% vs Q4 2022−21.4% vs Q3 2023
Net Income-$47.15K-$47.15K derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$929,805−16.1%
Operating Incomederived-$51,765N/M
Operating Cash Flowderived$308,436+18.6%
Free Cash Flowderived$310,016+25.0%
Margins · derived
Gross margin25.8%+1.9 pt vs Q4 2022
Operating margin-1.4%−5.1 pt vs Q4 2022
Net margin-1.3%−5.0 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $3.60M | $4.64M | $5.60M | $5.03M |
| Net Income | -$47.15K | $173.38K | -$4.87M | $144.35K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR